Atlas Trials

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Clinical trial NCT02974621 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02974621
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2017-12-07
Primary completion
2022-12-31
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.